Karus Therapeutics Extends Drug Discovery Programme to Target HDAC-6
23-Feb-2010 -
Karus Therapeutics Ltd, a company engaged in the discovery and development of molecular-targeted drugs to treat inflammation and cancer, announced it had extended its HDAC drug discovery programme to include small molecules that selectively inhibit HDAC-6, a target of emerging importance in the ...
anti-inflammatory drugs
diseases
Expression
+7